Journal: Journal of Innate Immunity
Article Title: Interleukin-6 Limits Host Susceptibility to Urinary Tract Infection by Promoting Urothelial Expulsion of Intracellular Bacteria
doi: 10.1159/000550787
Figure Lengend Snippet: IL-6 signaling through the IL-6 receptor limits intracellular UPEC and IBC formation in the urothelium in vivo. a IL-6 neutralization with intraperitoneal (IP) IL-6 antibody (IL-6ab) injection in WT mice inhibits pSTAT3 by rIL-6 given IP as compared to isotype control, IgG1. b IL-6ab-treated WT mice had increased IBC formation 6 hpi with 10 8 UPEC (strain CFT073) compared to IgG1-treated mice ( p = 0.0192, Mann-Whitney U test). c Blockade of IL-6R in WT mice leads to similar inhibition of pSTAT3 by rIL-6 given IP as compared to isotype control, IgG2b. d Increased IBC formation at 6 hpi ( p = 0.0063, unpaired t test). e Increased intracellular UPEC recovery from IL-6 KO vs. WT bladders 6 hpi based on in vivo gentamicin protection assay ( p = 0.0364, Mann-Whitney U test). f RIL-6 given IP to IL-6 KO mice restores pSTAT3, and decreases IBC recovery compared to PBS carrier injection at 6 hpi ( g ) that is sustained at 24 hpi ( h ) (strain CFT073) ( p = 0.0118, unpaired t test and 0.0134, Mann-Whitney U test). Each dot in ( b ), ( d ), ( e ), ( g ), and ( h ) represents an individual mouse with the line at the median value.
Article Snippet: For IL-6 and IL-6R neutralization, WT mice received 200 μL of intraperitoneal injection of either 1 mg of anti-mouse IL-6 antibody (BioXCell, Lebanon NH, clone MP5-20F3) versus rat IgG1 isotype control (BioXCell, clone HRPN), or 500 μg of IL-6R neutralizing antibody (BioXCell, clone 15A7) versus rat IgG2b isotype control (BioXCell, clone LTF-2) 24 h prior to IL-6 treatment or UTI.
Techniques: In Vivo, Neutralization, Injection, Control, MANN-WHITNEY, Inhibition